Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact.
Fiche publication
Date publication
février 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr DEDIEU Stéphane, Pr MORJANI Hamid, Dr BOULAGNON-ROMBI Camille, Dr BENNASROUNE Aline, Dr SCHNEIDER Christophe, Dr COLLIN Guillaume, Dr BENNASROUNE Amar
Tous les auteurs :
Ben Arfi K, Schneider C, Bennasroune A, Bouland N, Wolak-Thierry A, Collin G, Le CC, Toussaint K, Hachet C, Lehrter V, Dedieu S, Bouché O, Morjani H, Boulagnon-Rombi C, Appert-Collin A
Lien Pubmed
Résumé
Extracellular matrix components such as collagens are deposited within the tumor microenvironment at primary and metastatic sites and are recognized to be critical during tumor progression and metastasis development. This study aimed to evaluate the clinical and prognostic impact of Discoidin Domain Receptor 1 (DDR1) expression in colon cancers and its association with a particular molecular and/or morphological profile and to evaluate its potential role as a prognosis biomarker. Immunohistochemical expression of DDR1 was evaluated on 292 colonic adenocarcinomas. DDR1 was highly expressed in 240 (82.2%) adenocarcinomas. High DDR1 immunostaining score was significantly associated, on univariate analysis, with male sex, left tumor location, wild type status, mutated status, and Annexin A10 negativity. High DDR1 immunohistochemical expression was associated with shorter event free survival only. Laser capture microdissection analyses revealed that DDR1 mRNA expression was mainly attributable to adenocarcinoma compared to stromal cells. The impact of DDR1 expression on cell invasion was then evaluated by modified Boyden chamber assay using cell types with distinct mutational profiles. The invasion capacity of colon adenocarcinoma is supported by DDR1 expression. Thus, our results showed that DDR1 was highly expressed in most colon adenocarcinomas and appears as an indicator of worse event free survival.
Mots clés
colon cancer, discoidin domain receptor, event free survival, prognosis, survival
Référence
Cancers (Basel). 2022 Feb 13;14(4):